SimCorp A/S
Company Announcement no. 07/2021
On February 10, 2021 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR.
In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 10, 2021 to July 31, 2021.
The following transactions have been executed under the program:
Date | Number of shares | Average purchase price (DKK per share) | Amount (DKK) |
Accumulated under the program as of last announcement: | 41,900 | 787.14 | 32,981,225 |
March 1, 2021 | 3,500 | 755.53 | 2,644,355 |
March 2, 2021 | 3,500 | 761.86 | 2,666,510 |
March 3, 2021 | 4,000 | 747.15 | 2,988,600 |
March 4, 2021 | 4,000 | 724.74 | 2,898,960 |
March 5, 2021 | 4,000 | 719.28 | 2,877,120 |
Accumulated under the program following above purchases: | 60,900 | 772.69 | 47,056,770 |
Following above purchases, SimCorp holds 762,587 treasury shares corresponding to 1.9% of the share capital.
Purchases for an amount of EUR 13.7m (approx. DKK 101.7m) remain to be executed under the program.
Enquiries regarding this announcement should be addressed to:
Anders Hjort, Head of Investor Relations, SimCorp A/S (+45 3544 8822)
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
KH Group Oyj19.9.2025 14:20:51 CEST | Press release
Inside information: Carl Haglund appointed as CEO of KH Group Plc
F. Hoffmann-La Roche Ltd19.9.2025 14:15:00 CEST | Press release
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Ipsen Pharma19.9.2025 13:59:15 CEST | Press release
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Alvotech19.9.2025 13:45:00 CEST | Press release
Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
Yacht Club de Monaco19.9.2025 13:11:39 CEST | Press release
At Yacht Club de Monaco the 5th Monaco Smart & Sustainable Marina Rendezvous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom